CRPS, or complex regional pain syndrome, is a real, well-documented medical condition recognized by every major pain and medical organization in the world. It has standardized diagnostic criteria, measurable biological markers, and observable changes in nerve fibers, inflammatory chemicals, and even brain structure. The condition affects roughly 26 per 100,000 people each year, and despite its long history of being misunderstood or dismissed, the science behind it is now extensive and clear.
If you’re asking this question, you may be dealing with pain that others don’t take seriously, or you may be trying to understand a diagnosis someone close to you received. Either way, here’s what the evidence shows.
Why CRPS Has Been Doubted
Part of the skepticism around CRPS comes from its unusual presentation. The pain is often wildly out of proportion to the original injury. A minor fracture, a sprain, or even surgery can trigger lasting, severe pain in the affected limb, sometimes spreading beyond the original site. To an outside observer, the limb might not look injured anymore, which leads some people, including some clinicians, to question whether the pain is “real” or psychological.
The condition has also gone through many name changes over the centuries, which has contributed to confusion. A British navy surgeon first described it in 1812 after treating a soldier with relentless burning pain following a gunshot wound. It was later called “causalgia,” then “Sudeck’s atrophy” after a German surgeon documented the bone changes it causes, and eventually “reflex sympathetic dystrophy” (RSD). The International Association for the Study of Pain (IASP) adopted the name “complex regional pain syndrome” to unify these descriptions under one framework with formal diagnostic criteria.
The Biological Evidence
CRPS is not a pain disorder with no detectable physical basis. Research has identified several overlapping biological mechanisms that explain what’s happening in the body.
The most direct evidence comes from tissue biopsies. When researchers examine skin samples from CRPS-affected limbs, they find clear degeneration of small nerve fibers, specifically the thin C-type and Aδ-type fibers responsible for transmitting pain and temperature signals. Compared to the unaffected limb on the same person, the affected limb shows reduced density of these normal nerve fibers and an increase in abnormal fibers that amplify pain signals. This is physical nerve damage visible under a microscope.
CRPS also involves a measurable inflammatory response. People with the condition have elevated levels of several inflammatory signaling molecules in their skin, blood, and even spinal fluid. These molecules, which the immune system normally releases in response to injury, remain elevated for months rather than subsiding as they would during normal healing. The result is an imbalance: pro-inflammatory signals stay high while anti-inflammatory signals drop. This sustained inflammation sensitizes nerves, causes swelling, and drives the ongoing pain cycle. Animal studies have confirmed the connection directly: injecting one of these inflammatory molecules into tissue produces prolonged pain sensitivity in a dose-dependent way, meaning more inflammation equals more pain.
Perhaps most striking, brain imaging studies show that CRPS physically alters the brain’s sensory maps. Using magnetoencephalography, researchers found that the area of the brain’s surface dedicated to processing sensation from the affected hand actually shrinks and shifts position in CRPS patients. The degree of this reorganization strongly correlates with pain severity, with a correlation coefficient of 0.79, which is a remarkably tight relationship in pain research. This means the condition isn’t just happening in the limb. It’s rewriting how the brain processes sensation from that part of the body.
How CRPS Is Diagnosed
CRPS is diagnosed using the Budapest Criteria, a validated clinical framework accepted by the IASP and incorporated into the World Health Organization’s international disease classification (ICD-11). The criteria require:
- Continuing pain that is disproportionate to any triggering event
- Reported symptoms in at least three of four categories: abnormal pain sensitivity, temperature or skin color changes, swelling or sweating changes, and movement problems or changes to hair, nails, or skin
- Observable signs at the time of evaluation in at least two of those same four categories
- No other diagnosis that better explains the symptoms
This means a CRPS diagnosis isn’t based on a patient’s word alone. A clinician must directly observe physical signs during the examination: measurable temperature differences between limbs, visible skin color changes, swelling, sweating differences, reduced range of motion, tremor, or changes in hair and nail growth. These are all things that can be seen, touched, and measured.
Imaging can provide additional supporting evidence. A triple-phase bone scan, which tracks blood flow and bone metabolism in the affected limb, shows characteristic patterns in CRPS. Studies have found this scan reaches about 82% sensitivity in detecting the condition when using updated criteria, meaning it correctly identifies CRPS in roughly four out of five confirmed cases.
Type 1 vs. Type 2
CRPS is classified into two types, and the only difference is the nature of the triggering event. Type 1, previously called reflex sympathetic dystrophy, develops without a confirmed injury to a major nerve. This is the more common form and often follows fractures, sprains, or surgeries. Type 2, historically called causalgia, involves a known injury to a specific peripheral nerve. The symptoms, progression, and severity can be identical in both types.
About 2 in every 1,000 people who recover from a wrist fracture, one of the most common triggers, go on to develop CRPS. This makes it uncommon but far from rare, especially in orthopedic and surgical settings.
What CRPS Feels Like
The hallmark of CRPS is pain that doesn’t match the injury. A healed fracture continues to produce burning, throbbing, or stabbing pain weeks or months after the bone has mended. Many people develop allodynia, where normally painless contact like clothing brushing the skin or a light breeze becomes intensely painful. Others experience hyperalgesia, where a mildly painful stimulus like a pinprick feels dramatically worse than it should.
Beyond pain, the affected limb often looks visibly different. The skin may change color, appearing red, blue, or mottled. It may feel noticeably warmer or cooler than the same spot on the other side. Swelling is common, and over time the skin’s texture can change, becoming shiny or thin. Nails may grow faster or become brittle. Hair growth patterns may shift. The limb may become stiff, weak, or develop tremors. These visible, measurable changes are part of why the condition is no longer considered a mystery by the medical community, even if public awareness lags behind.
Why Some People Still Dismiss It
Despite the evidence, people with CRPS frequently report being disbelieved by family members, employers, and sometimes even healthcare providers. Several factors feed this. The condition is relatively uncommon, so many general practitioners encounter it rarely. Its symptoms can fluctuate, with worse days and better days, which can look inconsistent to observers who expect “real” conditions to be constant. And because the original injury is often minor or fully healed, the ongoing severity of symptoms can seem implausible to someone unfamiliar with nerve sensitization and neuroinflammation.
None of this changes the underlying biology. CRPS produces measurable nerve fiber loss, quantifiable inflammatory changes, and observable brain reorganization. It is classified in the ICD-11, recognized by the IASP, and diagnosable through validated clinical criteria with supporting imaging. The condition is as real as a fracture. The difference is that its mechanisms are harder to see without looking closely.